Effects of atorvastatin on MMPs and vWF in peripheral blood lymphocytes in patients of early chronic kidney disease with carotid artery plaque

doi:10.3877/cma.j.issn.2095-655X.2020.04.004

Abstract

Abstract:

Objective

To explore the effects of atorvastatin on matrix metalloproteinase (MMPs) and von Willebrand factor (vWF) in peripheral blood lymphocytes in patients of early chronic kidney disease (CKD) with carotid artery plaque.

Methods

From January to October 2017, 143 patients with stage 1-2 CKD and carotid artery plaque who visited the Kidney Department of the East Hospital of Shanghai Sixth People′s Hospital and Heze Municipal Hospital were selected. According to the random number table method, they were divided into the CKD group (n=76) and the treatment group (n=67), and 50 healthy people with normal physical examination in the corresponding period were selected as the control group. The treatment group was treated with atorvastatin for oral administration. After 6 months of treatment, blood lipid level and carotid intima-media thickness (IMT) of the 3 groups were compared, and the changes of MMP-2, MMP-9 and vWF levels of peripheral blood lymphocytes in the 3 groups were compared after 1, 2, 3 and 6 months of treatment.

Results

Compared to the control group, after 6 months of treatment, the triglycerides levels [(1.42±0.40)mmol/L, (3.58±0.78)mmol/L, (1.78±0.46)mmol/L], total cholesterol levels [(4.56±0.78)mmol/L, (6.88±1.39)mmol/L, (5.16±1.14)mmol/L], IMT levels [(0.78±0.23)mm, (1.56±0.43)mm, (1.06±0.22)mm] and peripheral blood lymphocytes of MMP-9 levels [(124.10±42.96)μg/L, (232.82±90.16)μg/L, (158.57±57.14)μg/L], MMP-2 levels [(141.09±44.98)μg/L, (262.82±110.98)μg/L, (154.48±56.86)μg/L] and vWF levels [(111.68±42.29)μg/L, (276.82±111.68)μg/L, (142.32±46.44)μg/L] in the CKD group and treatment group were significantly increased, with statistically significant differences (F=5.90, 4.28, 3.45, 11.34, 12.45, 12.35, all P<0.05). The levels of triglyceride, total cholesterol, IMT, MMP-9, MMP-2 and vWF levels in the treatment group were lower than those in the CKD group, all the differences were statistically significant (t=4.21, 1.22, 5.13, 4.90, 5.90, 10.00, all P<0.05).

Conclusions

In early CKD patients with carotid artery plaque, atorvastatin may play a role in stabilizing plaques by reducing MMP-2, MMP-9 and vWF levels in peripheral blood lymphocytes.

Key words: Atorvastatin, Chronic kidney disease, Lymphocyte, Matrix metalloproteinase, Von Willebrand factor

Zhongsen Qu, Yongchao Pan, Qingde Zhang. Effects of atorvastatin on MMPs and vWF in peripheral blood lymphocytes in patients of early chronic kidney disease with carotid artery plaque[J]. Chinese Journal of Diagnostics(Electronic Edition), 2020, 08(04): 231-236.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2020.04.004

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2020/V08/I04/231

Figures/Tables 5

References 21

[1]	Rosell A, Ortega-Aznar A, Alvarez-Sabin J，et al.Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke [J]．Stroke，2006，37(6): 1399-1406.
[2]	Zoungas S, Ristevski S, Lightfoot P, et al. Carotid artery intima-medial thickness is increased in chronic renal failure [J]．Clin Exp Pharmacol Physiol，2000，27(8): 639-641.
[3]	Tanaka S, Kanazawa I, Sugimoto T．Nerve conduction velocity is negatively associated with intima-media thickness and brachial-ankle pulse wave velocity in men with type 2 diabetes mellitus [J]．PLoS One，2018，13(12): e0209503.
[4]	Rasic S, Hadzovic-Dzuvo A, Rebic D，et al.Endothelial dysfunction in uremic patients on continuous ambulatory peritoneal dialysis (capd) [J]．Bosn J Basic Med Sci，2011，11(3): 153-157.
[5]	孙寅轶，王姝瑾，刘帮健，等.2型糖尿病并发阿尔茨海默病患者外周血淋巴细胞蛋白磷酸酯酶-2A的变化 [J/CD]．中华诊断学电子杂志，2019，7(2): 78-82.
[6]	Tan C, Liu Y, Li W，et al.Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis，based on measurements of plaque and intima-media thickness [J]．Atherosclerosis，2014，232(1): 199-203. URL
[7]	Gujral DM, Shah BN, Chahal NS, et al. Carotid intima-medial thickness as a marker of radiation-induced carotid atherosclerosis [J]．Radiother Oncol，2016，118(2): 323-329.
[8]	Mizuno T, Sato W, Ishikawa K, et al. Kdigo (kidney disease: Improving global outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury [J]．Oncology，2012，82(6): 354-359. URL
[9]	Holaj R, Spacil J, Petrasek J，et al.Intima-media thickness of the common carotid artery is the significant predictor of angiographically proven coronary artery disease [J]．Can J Cardiol，2003，19(6): 670-676.
[10]	Wada S, Koga M, Minematsu K，et al.Baseline carotid intima-media thickness and stroke recurrence during secondary prevention with pravastatin[J]．Stroke，2019，50(6): 1586-1589.
[11]	Ishikawa M, Sugawara H, Tsuji T，et al.Clinical significance of the coexistence of carotid artery plaque and white matter disease in patients with symptomatic cerebral infarction [J]．Clin Neurol Neurosurg，2017(163): 179-185.
[12]	Heider P, Pelisek J, Poppert H，et al.Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease [J]．Vasc Endovascular Surg，2009，43(6): 551-560.
[13]	Fathipour V, Khaki Z, Nassiri SM.Evaluation of matrix metalloproteinases (mmp)-2 and mmp-9 activity in serum and biochemical and hematological parameters in spontaneous canine cutaneous tumors before and after surgical treatment [J]．Vet Res Forum，2018，9(1): 19-26.
[14]	Pulido-Olmo H, Garcia-Prieto CF, Alvarez-Llamas G，et al.Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria [J]．Clin Sci (Lond)，2016，130(7): 525-538.
[15]	Zhang L, Chopp M, Jia L，et al.Atorvastatin extends the therapeutic window for tpa to 6 h after the onset of embolic stroke in rats [J]．J Cereb Blood Flow Metab，2009，29(11): 1816-1824.
[16]	Chen X, Zhuang X, Peng Z，et al.Intensive statin therapy for acute ischemic stroke to reduce the number of microemboli：a preliminary，randomized controlled study [J]．Eur Neurol，2018，80(3/4): 163-170.
[17]	Chang HR, Yang SF, Li ML，et al.Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease [J]．Clin Chim Acta，2006，366(1/2): 243-248.
[18]	Pawlak K, Mysliwiec M, Pawlak D．Peripheral blood level alterations of mmp-2 and mmp-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis [J]．Clin Biochem，2011，44(10/11): 838-843.
[19]	Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1，2 and 9 in the human coronary artery [J]．Atherosclerosis，2000，150(2): 245-253.
[20]	Sonneveld MA, van Dijk AC, van den Herik EG，et al.Relationship of von willebrand factor with carotid artery and aortic arch calcification in ischemic stroke patients [J]．Atherosclerosis，2013，230(2): 210-215. URL
[21]	del Zoppo GJ, Koziol JA.Recanalization and stroke outcome [J]．Circulation，2007，115(20): 2602-2605.

组别	例数	性别(例，男/女)	年龄(岁，±s)	血糖(mmol/L，±s)	总胆固醇(mmol/L，±s)	甘油三酯(mmol/L，±s)	IMT(mm，±s)	收缩压(mmHg，±s)	舒张压(mmHg，±s)	血清肌酐(μmol/L，±s)
对照组	50	27/23	47.66±6.12	5.36±0.47	4.13±0.82	1.58±0.32	0.71±0.13	124.82±14.61	78.64±8.84	85.56±37.52
CKD组	76	49/27	52.42±5.83	7.67±1.84^a	7.24±1.46^a	2.43±0.49^a	1.42±0.32^a	168.29±23.42^a	98.45±11.60^a	115.32±23.78^a
治疗组	67	41/26	54.60±4.82	7.34±1.66^a	6.94±1.27^a	2.89±0.57^a	1.36±0.27^a	161.40±22.56 ^a	92.78±10.70^a	111.99±27.22^a
统计量	?	χ²＝9.34	F＝7.07	F＝2.25	F＝2.97	F＝2.55	F＝0.58	F＝1.17	F＝0.87	F＝5.13
P值	?	0.90	0.54	0.04	0.04	0.03	0.00	0.02	0.00	0.00

组别	例数	性别(例，男/女)	年龄(岁，±s)	血糖(mmol/L，±s)	总胆固醇(mmol/L，±s)	甘油三酯(mmol/L，±s)	IMT(mm，±s)	收缩压(mmHg，±s)	舒张压(mmHg，±s)	血清肌酐(μmol/L，±s)
对照组	50	27/23	47.66±6.12	5.36±0.47	4.13±0.82	1.58±0.32	0.71±0.13	124.82±14.61	78.64±8.84	85.56±37.52
CKD组	76	49/27	52.42±5.83	7.67±1.84^a	7.24±1.46^a	2.43±0.49^a	1.42±0.32^a	168.29±23.42^a	98.45±11.60^a	115.32±23.78^a
治疗组	67	41/26	54.60±4.82	7.34±1.66^a	6.94±1.27^a	2.89±0.57^a	1.36±0.27^a	161.40±22.56 ^a	92.78±10.70^a	111.99±27.22^a
统计量	?	χ²＝9.34	F＝7.07	F＝2.25	F＝2.97	F＝2.55	F＝0.58	F＝1.17	F＝0.87	F＝5.13
P值	?	0.90	0.54	0.04	0.04	0.03	0.00	0.02	0.00	0.00

组别	例数	总胆固醇(mmol/L)	甘油三酯(mmol/L)	IMT(mm)
对照组	50	4.56±0.78	1.42±0.40	0.78±0.23
CKD组	76	6.88±1.39^a	3.58±0.78^a	1.56±0.43^a
治疗组	67	5.16±1.14^bc	1.78±0.46^c	1.06±0.22^c
F值	?	4.28	5.90	3.45
P值	?	0.03	0.00	0.03

组别	例数	总胆固醇(mmol/L)	甘油三酯(mmol/L)	IMT(mm)
对照组	50	4.56±0.78	1.42±0.40	0.78±0.23
CKD组	76	6.88±1.39^a	3.58±0.78^a	1.56±0.43^a
治疗组	67	5.16±1.14^bc	1.78±0.46^c	1.06±0.22^c
F值	?	4.28	5.90	3.45
P值	?	0.03	0.00	0.03

组别	例数	治疗前	治疗第1个月后	治疗第2个月后	治疗第3个月后	治疗第6个月后
对照组	50	126.47±40.94	132.46±44.51	128.68±39.28	131.52±46.32	124.10±42.96
CKD组	76	216.36±72.48^a	208.54±63.78^a	213.54±78.24^a	229.58±84.78^a	232.82±90.16^a
治疗组	67	229.14±80.56^b	192.46±70.21^b	176.48±68.31^bc	168.59±61.38^bc	158.57±57.14^bc
F值	?	9.93	9.00	9.42	10.63	11.34
P值	?	0.04	0.04	0.04	0.02	0.02

Please choose a citation manager

Content to export